Fibrogenic Growth Factors in Encapsulating Peritoneal Sclerosis

被引:18
作者
Braun, N. [1 ]
Reimold, F. [1 ,2 ]
Biegger, D.
Fritz, P. [3 ]
Kimmel, M. [1 ]
Ulmer, C. [4 ]
Alscher, M. D. [1 ]
机构
[1] Robert Bosch Krankenhaus, Div Gen Internal Med & Nephrol, Dept Internal Med, DE-70376 Stuttgart, Germany
[2] Robert Bosch Krankenhaus, Dr Margarete Fischer Bosch Inst Clin Pharmacol, DE-70376 Stuttgart, Germany
[3] Robert Bosch Krankenhaus, Div Pathol, Dept Diagnost Med, DE-70376 Stuttgart, Germany
[4] Robert Bosch Krankenhaus, Dept Surg, DE-70376 Stuttgart, Germany
来源
NEPHRON CLINICAL PRACTICE | 2009年 / 113卷 / 02期
关键词
Encapsulating peritoneal sclerosis; Fibrosis; Growth factors; Inflammation; Peritoneal dialysis; Vascular endothelial growth factor; VASCULAR-PERMEABILITY FACTOR; HUMAN MAST-CELLS; CLINICAL-APPLICATIONS; MORPHOLOGIC CHANGES; DIALYSIS TREATMENT; HEMODIALYSIS; TRYPTASE; MODEL; JAPAN; EXPRESSION;
D O I
10.1159/000228540
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Increased local levels of fibrogenic growth hormones contribute substantially to the process of encapsulating peritoneal sclerosis (EPS) in animal models. Methods: We analyzed probes from patients with normal kidney function (n = 10), with normal kidney function and inflammation (n = 10), on PD without (n = 10) and with EPS (n = 9). We investigated the degree of fibrosis and the number of vessels and vasculopathy. Additionally, we investigated the expression of NF kappa B, TGF beta 1, TGF beta 1 receptor, TGF beta 2, TGF beta 2 receptor, FGF-BP, CTGF and VEGF by immunohistochemistry. Results: In EPS, we found an exclusive upregulation of VEGF (normal 0, appendicitis 1.0 +/- 1.2, PD 1.7 +/- 1.8 and EPS 5.7 +/- 4.4; p < 0.0001), whereas in PD, CTGF was significantly increased (normal 6.0 +/- 2.8, appendicitis 7.3 +/- 2.5, PD 10.0 +/- 1.8 and EPS 7.3 +/- 2.1; p = 0.0059). The results for the TGF beta system and NF kappa B were not uniform, in EPS no increases were demonstrable. Vasculopathy was significantly more pronounced in EPS (normal 0.4 +/- 0.5, appendicitis 0.2 +/- 0.3, PD 1.0 +/- 0.7 and EPS 1.6 +/- 1.2; p < 0.0001) than in PD or inflammation (normal 30 +/- 16, appendicitis 82 +/- 48, PD 1,936 +/- 952 and EPS 2,613 +/- 1,209; p < 0.0001), whereas the density of vessels were decreased (normal 125 +/- 114, appendicitis 817 +/- 347, PD 81 +/- 57 and EPS 36 +/- 33; p < 0.0001). Conclusions: The process of EPS was associated with increased VEGF in the peritoneum. The reduced density of vessels compared with marked fibrosis could point to hypoxia as an inducer. Copyright (C) 2009 S. Karger AG, Basel
引用
收藏
页码:C88 / C95
页数:8
相关论文
共 36 条
  • [1] Afthentopoulos I E, 1998, Adv Ren Replace Ther, V5, P157
  • [2] ALSCHER DM, 2005, EDTNA ERCA J, V31, P129
  • [3] Peritoneal mast cells in peritoneal dialysis patients, particularly in encapsulating peritoneal sclerosis patients
    Alscher, Dominik M.
    Braun, Niko
    Biegger, Dagmar
    Fritz, Peter
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2007, 49 (03) : 452 - 461
  • [4] PRINCIPLES OF PERITONEAL DIALYSIS
    Alscher, Dominik Mark
    [J]. JOURNAL OF RENAL CARE, 2005, 31 (03) : 124 - 129
  • [5] Bird SD, 1998, PERITON DIALYSIS INT, V18, P626
  • [6] Human mast cells stimulate vascular tribe formation - Tryptase is a novel, potent angiogenic factor
    Blair, RJ
    Meng, H
    Marchese, MJ
    Ren, SL
    Schwartz, LB
    Tonnesen, MG
    Gruber, BL
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (11) : 2691 - 2700
  • [7] Encapsulating peritoneal sclerosis: An unpredictable and devastating complication of peritoneal dialysis
    Chin, AI
    Yeun, JY
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2006, 47 (04) : 697 - 712
  • [8] Combet S, 2000, J AM SOC NEPHROL, V11, P717, DOI 10.1681/ASN.V114717
  • [9] Hemodialysis versus peritoneal dialysis: A comparison of adjusted mortality rates
    Fenton, SSA
    Schaubel, DE
    Desmeules, M
    Morrison, HI
    Mao, Y
    Copleston, P
    Jeffery, JR
    Kjellstrand, CM
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1997, 30 (03) : 334 - 342
  • [10] Vascular endothelial growth factor: Basic science and clinical progress
    Ferrara, N
    [J]. ENDOCRINE REVIEWS, 2004, 25 (04) : 581 - 611